Provided herein is a topical antibiotic composition that includes an external antibiotic agent, one or more pharmaceutically acceptable excipients, and at least one of a cannabinoid, terpene, and flavonoid. Also provided is a method that includes topically administering to a skin surface of a subject (e.g., human) the topical antibiotic composition.

Provided herein is a topical antibiotic composition that includes an external antibiotic agent, one or more pharmaceutically acceptable excipients, and at least one of a cannabinoid, terpene, and flavonoid. Also provided is a method that includes topically administering to a skin surface of a subject (e.g., human) the topical antibiotic composition.

Disclosed herein is a compound of formula I:

##STR00001##

where m, n and R.sup.1 are as defined herein. Also disclosed herein are uses of the compound.

Disclosed herein is a compound of formula I:

##STR00001##

where m, n and R.sup.1 are as defined herein. Also disclosed herein are uses of the compound.

Disclosed are antimicrobial compositions and formulations directed against a broad range of bacteria and Pseudomonas aeruginosa biofilms. In an aspect, the compositions and formulations do not engender resistance. In an aspect, in combination with antibiotics, the compositions and formulations slow the development of antibiotic-resistance and greatly improve bacterial susceptibility to multiple classes of antibiotics.

Disclosed are antimicrobial compositions and formulations directed against a broad range of bacteria and Pseudomonas aeruginosa biofilms. In an aspect, the compositions and formulations do not engender resistance. In an aspect, in combination with antibiotics, the compositions and formulations slow the development of antibiotic-resistance and greatly improve bacterial susceptibility to multiple classes of antibiotics.

Disclosed are antimicrobial compositions and formulations directed against a broad range of bacteria and Pseudomonas aeruginosa biofilms. In an aspect, the compositions and formulations do not engender resistance. In an aspect, in combination with antibiotics, the compositions and formulations slow the development of antibiotic-resistance and greatly improve bacterial susceptibility to multiple classes of antibiotics.

The present application relates to a pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of COVID-19. More specifically, disclosed in the present application is a composition used for prevention or treatment of COVID-19, comprising a polyriboinosinic-polyribocytidylic acid, an antibiotic or polyamino compound, a positive ion, and an optional antigen derived from novel coronavirus SARS-CoV-2. Also provided is use of the composition in preparation of a drug or vaccine for prevention or treatment of novel coronavirus SARS-CoV-2.

The present application relates to a pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of COVID-19. More specifically, disclosed in the present application is a composition used for prevention or treatment of COVID-19, comprising a polyriboinosinic-polyribocytidylic acid, an antibiotic or polyamino compound, a positive ion, and an optional antigen derived from novel coronavirus SARS-CoV-2. Also provided is use of the composition in preparation of a drug or vaccine for prevention or treatment of novel coronavirus SARS-CoV-2.

A composition, comprising a hydrogel matrix and microparticles within said matrix, said matrix comprising a cross-linkable protein and a cross-linking agent, wherein said cross-linking agent is able to cross-link said cross-linkable protein, wherein said microparticles comprise a drug.